Leukemia Gene Atlas – A Public Platform for Integrative Exploration of Genome-Wide Molecular Data by Hebestreit, Katja et al.
Leukemia Gene Atlas – A Public Platform for Integrative
Exploration of Genome-Wide Molecular Data
Katja Hebestreit
1.,S o ¨ren Gro ¨ttrup
1., Daniel Emden
1, Jannis Veerkamp
1, Christian Ruckert
1, Hans-
Ulrich Klein
1, Carsten Mu ¨ller-Tidow
2, Martin Dugas
1*
1Institute of Medical Informatics, University of Muenster, Muenster. Germany, 2Department of Medicine, Hematology and Oncology, University of Muenster, Muenster,
Germany
Abstract
Leukemias are exceptionally well studied at the molecular level and a wealth of high-throughput data has been published.
But further utilization of these data by researchers is severely hampered by the lack of accessible integrative tools for
viewing and analysis. We developed the Leukemia Gene Atlas (LGA) as a public platform designed to support research and
analysis of diverse genomic data published in the field of leukemia. With respect to leukemia research, the LGA is a unique
resource with comprehensive search and browse functions. It provides extensive analysis and visualization tools for various
types of molecular data. Currently, its database contains data from more than 5,800 leukemia and hematopoiesis samples
generated by microarray gene expression, DNA methylation, SNP and next generation sequencing analyses. The LGA allows
easy retrieval of large published data sets and thus helps to avoid redundant investigations. It is accessible at www.
leukemia-gene-atlas.org.
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Introduction
Recent advances in high-throughput technologies allow to
collect unprecedented amounts of genomic, trancriptomic and
epigenomic data. Even single studies can be based on genome
wide microarray expression data of more than 2 000 patients [1].
Novel sources of high-throughput data such as those based on next
generation sequencing promise to further enhance molecular
analyses of leukemias on a genome wide level [2,3]. High-
throughput data are usually submitted to a public repository where
they can be accessed and used for further analyses. These data
have the potential to substantially accelerate and enhance further
research [4,5]. For example, for newly identified inactivating
mutations or gene deletions it is of interest to identify gene
expression patterns across hematopoietic differentiation and in
different hematological malignancies. Furthermore, comparison of
a new data set with published data can confirm results and
accelerate discoveries [6]. Rapid and reliable access to published
data sets can therefore save costs and speed up research. However,
the access to published data by non-bioinformaticians is time-
consuming, error-prone and often outright not successful. Thus,
there is a need for a repository that enables researchers to retrieve
information from already published data and helps to avoid
redundant investigations [7]. The requirements for such a
repository include the following: It should contain a wide range
of molecular data types. The samples corresponding to the data
should be annotated thoroughly with regard to leukemia, both
clinically and biologically. The repository should provide search
and browse functions as well as analysis and visualization tools to
process the data. Besides, the repository should be freely
accessible.
Here, we describe the Leukemia Gene Atlas (LGA), a novel
online bioinformatics tool that provides comprehensive, easy and
fast access to published genome wide data sets in hematopoiesis
and hematological malignancies. In the following section we
describe the architecture of the LGA paying particular attention to
the database and the data stored therein. The primary purpose of
the LGA is to support translational research and biomarker
discovery in hematology.
Materials and Methods
The LGA consists of three components: database, data analysis
module and web-based user-interface, Figure 1. The database
stores the molecular data together with all available information
from publications and constitutes the centerpiece of the LGA. This
database can be accessed using search functions by a user-friendly
web front-end. This front-end also allows conducting data
analyses. In the following sections these components are described
in more detail.
The Database
The database (PostgreSQL [8]) scheme is kept flexible to
include biologically and technically highly diverse experiments,
Table 1. Currently, the database contains studies based on DNA-
methylation, gene expression, copy number/genotype, and next-
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aspects such as prediction of molecular subtypes of leukemias,
research of human hematopoiesis and the analysis of transcription
factor binding sites. The majority of these molecular data was
imported from Gene Expression Omnibus (GEO) [9] and new
data sets are continuously added. Data published in peer-reviewed
journals only is considered to be integrated. And only after passing
a quality control and, if necessary, additional preprocessing steps,
the molecular data is added semi-automatically. Data preprocess-
ing and import into the database are generally done in R/
Bioconductor [10,11]. In addition to the molecular data, basic
information about the underlying experiments is stored as well as a
link to the related publications. Clinical and biological character-
istics of the respective samples, patients and cell lines are deposited
as well. Considerable effort was made to extract as many attributes
as possible, particularly with regard to leukemias. For this purpose
the sample characteristics arising from GEO were completed by
further attributes obtained manually from the corresponding
publication. Where available, survival data was also included.
Currently, there are more than 30 clinical and biological attributes
to describe samples and patients respectively.
Figure 1. Overview of the LGA architecture. Data is imported from several online repositories and the medical literature into the LGA database.
An analysis module processes the molecular data. The application server handles data transfer between database and analysis module and can be
accessed through a web interface. It executes queries and forwards data and analysis results to the client.
doi:10.1371/journal.pone.0039148.g001
Table 1. Overview of data in the LGA.
Publication Samples Experiment type Sample size
Kohlmann et al. Leukemia 2010 AML Gene expression (microarray) 251
Haferlach et al. J Clin Oncol 2010 ALL/AML/CLL/CML/MDS/healthy Gene expression (microarray) 3248
Figueroa et al. Cancer cell 2010 AML/Healthy DNA-methylation (microarray) 352
Verhaak et al. Haematologica 2010 AML Gene expression (microarray) 461
Valk et al. N Engl J Med 2010 AML/Healthy Gene expression (microarray) 293
Bullinger et al. Leukemia 2010 AML/Diagnosis/Remission Genotype (microarray) 328
Kohlmann et al. J Clin Oncol 2010 CMML DNA sequencing 81
Gutierrez et al. Leukemia 2005 AML Gene expression (microarray) 43
Novershtern et al. Cell 2011 Human hematopoietic cells Gene expression (microarray) 211
Figueroa et al. Cancer Cell 2010 AML/Healthy Gene expression, DNA-methylation (microarray) 411
Kohlmann et al. Leukemia 2011 CMML DNA sequencing 18
Tijssen et al. Developmental cell 2011 Primary human megakaryocytes ChIP-sequencing 5
Eppert et al. Nat Med 2011 AML/Primary human cord blood Gene expression (microarray) 105
Schenk et al. Nat Med 2012 Treated cell-lines (TEX/HL60) Gene expression (microarray), ChIP-sequencing 30
Bruns et al. Leukemia 2009 Hematopoietic stem cells in CML Gene expression (microarray) 47
Diaz-Blanco et al. Leukemia 2007 Hematopoietic stem cells in CML Gene expression (microarray) 17
doi:10.1371/journal.pone.0039148.t001
Leukemia Gene Atlas
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also includes important results arising from analyses of this
molecular data. Results might be, for example, tables of
differentially expressed genes, gene ontology terms or copy
number alterations. Regarding next-generation sequencing stud-
ies, tables of discovered mutations or binding sites are deposited.
These results are usually extracted from the articles and
supplementary tables, or are generated by ourselves according to
the data analysis description in the publication.
In addition, the result tables comprise an extract of the
COSMIC database [12]. For each hematopoietic disease and
investigated gene the number of samples which have been tested
for mutations and the number of detected mutations in this gene
are included.
The Web Site
The LGA database is freely accessible via a web site (www.
leukemia-gene-atlas.org) which supports selection and analysis of
samples with comprehensive search and analysis functions. Data,
result tables and generated graphics can be exported for further
downstream analysis.
For each experiment, basic publication and data source
information is provided as well as experimental details such as
data type (e.g. gene expression or DNA methylation), platform
used (e.g. which microarray or sequencer), and the number of
analyzed samples.
Experiments can be filtered by sample or study characteristics,
e.g. data type, leukemia subtype or karyotype. Via filters the user
may create collections of samples by their biological and clinical
characteristics. The data of defined collections can be analyzed
and downloaded.
For some analysis functions it can be useful or necessary to
specify genes of interest. User-defined lists of relevant genes or
features (e.g. Affymetrix probe sets) can be added to the predefined
ones, for instance genes associated with apoptosis or cell cycle.
Searching for genes and genome coordinates within result tables
is a key functionality of the LGA. For example, groups of samples
can be identified whose expression or methylation patterns
significantly differ for certain genes of interest. In addition, the
result search automatically scans a summary of the COSMIC
database and displays the number of patients harboring mutations
Figure 2. Populations of human hematopoietic cells. 38 hematopoietic cell populations are shown with their respective positions in
hematopoiesis. Cells called as ‘‘progenitors’’ in the analysis are marked by a red box, ‘‘non-progenitor’’ cells are marked by a gray box. Figure adapted
from Novershtern et al. [9].
doi:10.1371/journal.pone.0039148.g002
Leukemia Gene Atlas
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hyperlink forwards the user to COSMIC Biomart [13] with filters
set to the corresponding gene and disease.
Data Analysis Tools
The web site provides a wide range of analysis tools for
processing stored data.
Figure 3. Usage of the LGA web interface. (Above) Experiment view with information on the integrated study [15] (above), sample
characteristics (hidden, in the middle) and stored result tables (below). Genes with RUNX1 binding sites are copied from a table of peak annotations
and stored as a gene list. (Middle) Groups of samples from [14] are defined in the analysis tab. (Below) Selecting the stored gene list (genes with
RUNX1 binding sites) and performing principle component analysis on the selected groups of samples from [14].
doi:10.1371/journal.pone.0039148.g003
Figure 4. The role of RUNX1 and its binding sites in leukemias. (A) Screenshot of a t-test result table with the 33 most differentially expressed
genes with RUNX1 binding sites in progenitor and non-progenitor cells. (B) Distribution of RUNX1 expression for different leukemic disease states. (C)
Heat map and hierarchical clustering of patients with acute lymphoblastic leukemia and non-leukemia samples with healthy bone marrows for gene
expression of genes with RUNX1 binding sites and highest variances over all samples. The phenotype color grid at the top represents the sample
characteristics. (D) Kaplan Meier curves of event-free survival for patients with acute myeloid leukemia with low (#33% quantile), median (.33%
quantile and #66% quantile), and high RUNX1 expression (.66% quantile).
doi:10.1371/journal.pone.0039148.g004
Leukemia Gene Atlas
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across samples and groups of samples, bar charts are available with
an integrated phenotype color grid as well as box plots. The
phenotype color grid is an extension for visualization tools
representing clinical and biological characteristics of the samples
and enabling identification of possible correlations between
phenotypes and molecular data.
Unsupervised analyses by means of principal component
analysis and hierarchical clustering are available for exploration
of gene expression and DNA-methylation data. Results of
hierarchical clustering are presented by dendrograms together
with a heat map where columns correspond to the samples and
rows to the features of the platform. It is extended by the
phenotype color grid to support the identification of potential
subgroups of samples by their molecular data.
Testing for differential expression or DNA-methylation in
groups of samples is possible via an ANOVA or Welch’s t-test
with adjustment for multiple testing [14].
Survival analysis is provided for data sets with available survival
annotation. Samples can be grouped either by their molecular
data (expression/DNA-methylation profile of a specific gene) or by
their clinical and biological characteristics. Survival times of these
groups of samples can be compared by Kaplan-Meier-Plots and
log-rank test.
All data analysis functions are implemented in R/Bioconductor
[10,11].
As an established visualization tool we embedded the Integra-
tive Genomics Viewer (IGV) [15]. It supports all data types of the
LGA and enables interactive exploration of large data sets from
multiple studies in parallel.
Results
In the following, we demonstrate the usability of the LGA to
generate or substantiate new hypotheses based on published
genomic data sets. The presented example integrates ChIP-seq
and gene expression data sets from four different studies. All
methods and data are provided by the LGA and results were
directly generated from the LGA web site.
RUNX1 is a regulatory gene in hematopoiesis and plays a key
role in the development of leukemias [16]. To investigate the role
of RUNX1 in hematopoiesis we classified 38 distinct populations of
human hematopoietic cells [17] into progenitors and non-
progenitors (Figure 2). Next, we selected all genes that have a
RUNX1 binding site according to the ChIP-seq data set from
Tijssen et al. [18]. Clustering based on the expression values of
these RUNX1 regulated genes separated the progenitor from the
non-progenitor cells (Figure 3). T-tests revealed that 31 of the 33
most differentially expressed genes with RUNX1 binding sites
(FDR ,0.001) were overexpressed in progenitors (Figure 4A). To
investigate the role of RUNX1 in leukemias we compared RUNX1
expression for nine different leukemias and healthy controls in
more than 2000 leukemia and control specimens derived from the
MILE study [1]. RUNX1 was notably down regulated in chronic
lymphoid leukemia samples (Figure 4B). Hierarchical clustering
based on all genes with RUNX1 binding sites showed a strong
subdivision of the samples into disease states, e.g. acute
lymphoblastic leukemia separated from controls (Figure 4C; with
the phenotype color grid).
Searching for RUNX1 in published results across all studies
revealed differential expression for groups of leukemias (Figure S1)
and that mutations in RUNX1 occur frequently. The extract of
COSMIC shows that there are 90 RUNX1 mutations in 688
patients with acute myeloid leukemia (Figure S2). In a sequencing
study [19] seven different RUNX1 mutations in chronic myelo-
monocytic leukemia samples have been detected. Six of these
seven mutations are single nucleotide changes (Figure S2). A
survival analysis of 293 patients with acute myeloid leukemia taken
from Verhaak et al. [20] revealed an association between event-
free survival and RUNX1 expression: a reduced expression of
RUNX1 was associated with better outcome (Figure 4D).
Discussion
In the literature, leukemia samples are thoroughly characterized
in terms of mutation status and cytogenetics. Most repositories and
databases lack the ability to make use of these important and
helpful data. Gene Expression Omnibus (GEO) [9] has its
limitations regarding queries and analyses. Queries for studies
are currently possible via keywords only, specific leukemia related
annotations are missing and analysis tools are not recommended
for robust systematic analyses [9,21]. Analyses provided in
ArrayExpress [22] are currently limited to gene expression data
and do not include the sample’s karyotypes or mutations as
condition query. User-defined custom analyses are currently not
possible. Oncomine [23] is a commercial cancer microarray
database storing results of differential expression analyses.
Available gene signatures are predominantly restricted to the
comparison of cancer vs. normal samples or a cancer subtype vs.
all other subtypes and the user cannot perform analyses on
alternative groups of samples. Other repositories, such as dbGAP
database of genotypes and phenotypes [24], The Cancer Genome
Atlas [25] and the Atlas of Genetics and Cytogenetics in Oncology
and Heamatology [26] are less suitable for re-analysis and
integration of published high-throughput data.
To our knowledge, the LGA is the first repository custom-
tailored to the requirements of the leukemia research community
in the field of molecular and clinical data. It provides extensive
access to published leukemia data and thus helps to interpret
newly measured data. It comprises several types of molecular data
and supports integration of data types. The corresponding samples
are annotated extensively. The user can choose between eight
different analysis and visualization tools. Further data sets and data
types, e.g. based on ChIP-chip or reduced representation bisulfite
sequencing experiments, are continuously added.
Taken together, the LGA fills an urgent need for a usable and
multifaceted repository for leukemia and hematopoiesis data sets.
Its easy accessibility can enhance further leukemia research and
biomarker development.
Supporting Information
Figure S1 Different RUNX1 expression. Screenshot of an
extract of results for RUNX1 search showing the groups of samples
where RUNX1 is differentially expressed for three experiments.
(TIF)
Figure S2 Mutations in RUNX1. Screenshot of an extract of
results for RUNX1 search showing detected mutations in patients
with chronic myelomonocytic leukemia (above) and the number of
detected mutations per disease state in COSMIC (below).
(TIF)
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